Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis

Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis

Abstract Background Data are currently insufficient to support the use of adjuvant chemotherapy (ACT) after surgical resection for stage II or III non-small cell lung cancer (NSCLC) in patients aged ≥ 75 years. In this study we evaluated efficacy and safety profile of ACT in this population. Methods...

Full description

Bibliographic Details
Main Authors: Miriam Blasi, Martin E. Eichhorn, Petros Christopoulos, Hauke Winter, Claus Peter Heußel, Felix J. Herth, Rami El Shafie, Katharina Kriegsmann, Mark Kriegsmann, Albrecht Stenzinger, Helge Bischoff, Michael Thomas, Jonas Kuon
Format: Article
Language:English
Published: BMC 2022-06-01
Series:BMC Pulmonary Medicine
Subjects:
Adjuvant chemotherapy
Elderly
Non-small cell lung cancer
Online Access:https://doi.org/10.1186/s12890-022-02043-6

Internet

https://doi.org/10.1186/s12890-022-02043-6

Similar Items